اخبار و اعلانات

 آمار

تعداد نشریات282
تعداد نشریات سازمان80
تعداد شماره‌ها3,230
تعداد مقالات35,784
تعداد مشاهده مقاله54,009,472
تعداد دریافت فایل اصل مقاله93,167,858
AbdulHameed Saeed, V, Mohammed, N. A. K. (1402). Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients. سامانه مدیریت نشریات علمی, 78(3), 981-988. doi: 10.22092/ari.2022.360239.2566
V AbdulHameed Saeed; N. A. K Mohammed. "Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients". سامانه مدیریت نشریات علمی, 78, 3, 1402, 981-988. doi: 10.22092/ari.2022.360239.2566
AbdulHameed Saeed, V, Mohammed, N. A. K. (1402). 'Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients', سامانه مدیریت نشریات علمی, 78(3), pp. 981-988. doi: 10.22092/ari.2022.360239.2566
AbdulHameed Saeed, V, Mohammed, N. A. K. Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients. سامانه مدیریت نشریات علمی, 1402; 78(3): 981-988. doi: 10.22092/ari.2022.360239.2566

Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients

Archives of Razi Institute
مقاله 25، دوره 78، شماره 3، مرداد و شهریور 2023، صفحه 981-988    اصل مقاله (513.92 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.360239.2566
نویسندگان
V AbdulHameed Saeed1؛ N. A. K Mohammed* 2
1Department of Basic Science, College of Medicine, Hawler Medical University, Erbil, Iraq
2Pharmacology Unit, Department of Basic sciences, College of Medicine, Hawler Medical University, Erbil, Iraq
چکیده
One of the breast cancer subtypes, epidermal growth factor receptor 2 (HER2), accounts for 15% of all breast cancers and is characterized by aggressive behavior and a poor prognosis. For patients with HER2-positive breast cancer, trastuzumab, a monoclonal antibody that targets HER2 receptors, is prescribed in addition to chemotherapy to increase their chances of survival. However, the high expense of this treatment makes it impossible for patients in developing nations to easily afford it and undergo this biological therapy. Consequently, trastuzumab biosimilars have been launched as a substitute that offers comparable effectiveness at a reduced price. This study aimed to compare the biological activity and cardiac safety of reference trastuzumab with biosimilar trastuzumab by monitoring serum levels of the tumor biomarker CA15-3 and evaluating N-terminal pro-B-type natriuretic peptide (NT-proBNP) for the adverse cardiac effects of both treatments on HER2-positive breast cancer patients before and after six cycles of biological therapy. This prospective research was performed on 36 females with metastatic and early-stage HER2-positive breast cancer who visited the Oncology Department at Rizgary Hospital, Erbil, Iraq. The patients were within the age range of 30-80 years old. Eighteen individuals received reference trastuzumab, while the remaining 18 received both chemotherapy and biosimilar trastuzumab. Each patient had a data sheet that contained details from hospital-reserved files. In the Herceptin group, there was an insignificant difference in the median of CA15-3, while no significant difference was detected between the means of NT-proBNP before and after treatment. In the biosimilar group, there was a significant reduction in the median CA15-3 as well as a significant increase in the level of NT-proBNP before and after the treatment. Evaluation of the association of trastuzumab-induced cardiotoxicity during breast cancer treatment with different factors indicated that there might be an increased risk of cardiotoxicity after trastuzumab treatment.
کلیدواژه‌ها
Biosimilar trastuzumab؛ Breast cancer؛ Chemotherapy؛ Her2-positive breast cancer؛ Reference trastuzumab
سایر فایل های مرتبط با مقاله
مراجع
  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209-49.
  2. Harbeck N, Rastogi P, Shahir A, Johnston S, O'Shaughnessy J. Letter to the Editor for ‘Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study’. Ann Oncol. 2022;33(2):227-8.
  3. Yang Y, Zhang H, Zhang M, Meng Q, Cai L, Zhang Q. Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients. Oncol Lett. 2017;14(6):7549-56.
  4. Wang X, Yu H, Lu D, Zhang J, Deng W. Label free detection of the breast cancer biomarker CA15. 3 using ZnO nanorods coated quartz crystal microbalance. Sens Actuators B Chem. 2014;195:630-4.
  5. Blancas I, Martín-Pérez FJ, Garrido JM, Rodríguez-Serrano F. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Breast. 2020;54:106-13.
  6. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA: Cancer J Clin. 2011;61(6):408-18.
  7. Dobi Á, Kelemen G, Kaizer L, Weiczner R, Thurzó L, Kahán Z. Breast cancer under 40 years of age: increasing number and worse prognosis. Pathol Oncol Res. 2011;17(2):425-8.
  8. Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017;69(3):313-7.
  9. Chen H-l, Zhou M-q, Tian W, Meng K-x, He H-f. Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PloS One. 2016;11(10):e0165409.
  10. Kataoka A, Tokunaga E, Masuda N, Shien T, Kawabata K, Miyashita M. Clinicopathological features of young patients (< 35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study. Breast Cancer. 2014;21(6):643-50.
  11. Ellingjord-Dale M, Vos L, Vik Hjerkind K, Hjartåker A, Russnes HG, Tretli S, et al. Number of risky lifestyle behaviors and breast cancer risk. JNCI Cancer Spectrum. 2018;2(3):pky030.
  12. Liu K, Zhang W, Dai Z, Wang M, Tian T, Liu X, et al. Association between body mass index and breast cancer risk: Evidence based on a dose–response meta-analysis. Cancer Manag Res. 2018;10:143.
  13. Picon‐Ruiz M, Morata‐Tarifa C, Valle‐Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA: Cancer J Clin. 2017;67(5):378-97.
  14. Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17(10):1240-5.
  15. Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New technologies for analysis of extracellular vesicles. Chem Rev. 2018;118(4):1917-50.
  16. Nicolini A, Ferrari P, Duffy MJ, editors. Prognostic and predictive biomarkers in breast cancer: Past, present and future. Seminars in cancer biology; 2018: Elsevier.
  17. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015;33(24):2695.
  18. Perrier A, Boelle P-Y, Chrétien Y, Gligorov J, Lotz J-P, Brault D, et al. An updated evaluation of serum sHER2, CA15. 3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies. PloS One. 2020;15(1):e0227356.
  19. Curigliano G, Cardinale D, Suter T, Plataniotis G, De Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23:55-66.
  20. Meijers WC, van der Velde AR, Muller Kobold AC, Dijck‐Brouwer J, Wu AH, Jaffe A, et al. Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail. 2017;19(3):357-65.
  21. Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol. 2017;35(8):878-84.
  22. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893-911.
  23. Andersson AE, Linderholm B, Giglio D. Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab. Acta Oncologica. 2021;60(4):475-81.
آمار
تعداد مشاهده مقاله: 2,726
تعداد دریافت فایل اصل مقاله: 7,436


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب